Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3556381rdf:typepubmed:Citationlld:pubmed
pubmed-article:3556381lifeskim:mentionsumls-concept:C0001792lld:lifeskim
pubmed-article:3556381lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:3556381lifeskim:mentionsumls-concept:C0678823lld:lifeskim
pubmed-article:3556381lifeskim:mentionsumls-concept:C0025387lld:lifeskim
pubmed-article:3556381pubmed:issue6lld:pubmed
pubmed-article:3556381pubmed:dateCreated1987-5-18lld:pubmed
pubmed-article:3556381pubmed:abstractTextWe have determined the pharmacokinetics of meptazinol after its intravenous and intramuscular administration in a crossover study in 7 elderly hospital in-patients (greater than 70 years), and have compared with the results from 14 healthy, young volunteers (ages 20-40 years). The systemic availability after i.m. administration was comparable to that after i.v. administration, a result consistent with the physicochemical properties of the drug. There was a slight, but statistically significant (p less than 0.01) prolongation in t1/2Z in the elderly (mean 2.93 h) compared with the young (mean 2.06 h). This was associated with a 25% lower clearance in the elderly rather than with any alteration in volume of distribution. However, these changes would not appear to be substantial enough to require a revised dosage recommendation for meptazinol for this age group.lld:pubmed
pubmed-article:3556381pubmed:languageenglld:pubmed
pubmed-article:3556381pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3556381pubmed:citationSubsetIMlld:pubmed
pubmed-article:3556381pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3556381pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3556381pubmed:statusMEDLINElld:pubmed
pubmed-article:3556381pubmed:issn0031-6970lld:pubmed
pubmed-article:3556381pubmed:authorpubmed-author:FranklinR ARAlld:pubmed
pubmed-article:3556381pubmed:authorpubmed-author:LewisR RRRlld:pubmed
pubmed-article:3556381pubmed:authorpubmed-author:GrahamD FDFlld:pubmed
pubmed-article:3556381pubmed:authorpubmed-author:MurrayG RGRlld:pubmed
pubmed-article:3556381pubmed:authorpubmed-author:BollandM EMElld:pubmed
pubmed-article:3556381pubmed:issnTypePrintlld:pubmed
pubmed-article:3556381pubmed:volume31lld:pubmed
pubmed-article:3556381pubmed:ownerNLMlld:pubmed
pubmed-article:3556381pubmed:authorsCompleteYlld:pubmed
pubmed-article:3556381pubmed:pagination733-6lld:pubmed
pubmed-article:3556381pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:3556381pubmed:meshHeadingpubmed-meshheading:3556381-...lld:pubmed
pubmed-article:3556381pubmed:meshHeadingpubmed-meshheading:3556381-...lld:pubmed
pubmed-article:3556381pubmed:meshHeadingpubmed-meshheading:3556381-...lld:pubmed
pubmed-article:3556381pubmed:meshHeadingpubmed-meshheading:3556381-...lld:pubmed
pubmed-article:3556381pubmed:meshHeadingpubmed-meshheading:3556381-...lld:pubmed
pubmed-article:3556381pubmed:meshHeadingpubmed-meshheading:3556381-...lld:pubmed
pubmed-article:3556381pubmed:meshHeadingpubmed-meshheading:3556381-...lld:pubmed
pubmed-article:3556381pubmed:meshHeadingpubmed-meshheading:3556381-...lld:pubmed
pubmed-article:3556381pubmed:meshHeadingpubmed-meshheading:3556381-...lld:pubmed
pubmed-article:3556381pubmed:meshHeadingpubmed-meshheading:3556381-...lld:pubmed
pubmed-article:3556381pubmed:meshHeadingpubmed-meshheading:3556381-...lld:pubmed
pubmed-article:3556381pubmed:year1987lld:pubmed
pubmed-article:3556381pubmed:articleTitlePharmacokinetics of meptazinol after parenteral administration in the elderly.lld:pubmed
pubmed-article:3556381pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3556381pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3556381pubmed:publicationTypeRandomized Controlled Triallld:pubmed